Nothing Special   »   [go: up one dir, main page]

MX2023012633A - Metodos de tratamiento de la enfermedad de injerto contra hospedero. - Google Patents

Metodos de tratamiento de la enfermedad de injerto contra hospedero.

Info

Publication number
MX2023012633A
MX2023012633A MX2023012633A MX2023012633A MX2023012633A MX 2023012633 A MX2023012633 A MX 2023012633A MX 2023012633 A MX2023012633 A MX 2023012633A MX 2023012633 A MX2023012633 A MX 2023012633A MX 2023012633 A MX2023012633 A MX 2023012633A
Authority
MX
Mexico
Prior art keywords
methods
host disease
versus host
graft versus
treating graft
Prior art date
Application number
MX2023012633A
Other languages
English (en)
Inventor
Naro Antonio Francesco Di
Original Assignee
Adienne S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adienne S A filed Critical Adienne S A
Publication of MX2023012633A publication Critical patent/MX2023012633A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción se relaciona con métodos de uso de un anticuerpo anti-CD26 y sus fragmentos de unión a antígeno 5 para el tratamiento de la enfermedad de injerto contra hospedero.
MX2023012633A 2021-05-13 2022-05-13 Metodos de tratamiento de la enfermedad de injerto contra hospedero. MX2023012633A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163201805P 2021-05-13 2021-05-13
PCT/IB2022/054501 WO2022238978A1 (en) 2021-05-13 2022-05-13 Methods of treating graft versus host disease

Publications (1)

Publication Number Publication Date
MX2023012633A true MX2023012633A (es) 2023-11-09

Family

ID=81850738

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012633A MX2023012633A (es) 2021-05-13 2022-05-13 Metodos de tratamiento de la enfermedad de injerto contra hospedero.

Country Status (10)

Country Link
EP (1) EP4337693A1 (es)
JP (1) JP2024517337A (es)
KR (1) KR20240007229A (es)
CN (1) CN117580866A (es)
AU (1) AU2022271679A1 (es)
BR (1) BR112023022724A2 (es)
CA (1) CA3218127A1 (es)
IL (1) IL308373A (es)
MX (1) MX2023012633A (es)
WO (1) WO2022238978A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69932644T2 (de) 1998-04-15 2007-08-09 Genentech, Inc., South San Francisco Menschliches Protein mit in vitro antiproliferativer Aktivität.
CA2446806A1 (en) 2001-05-11 2002-11-21 Board Of Regents, The University Of Texas System Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26
AU2006272713A1 (en) 2005-07-22 2007-02-01 Y's Therapeutics Co, Ltd. Anti-CD26 antibodies and methods of use thereof
EP2131863A4 (en) * 2007-03-14 2012-07-11 Univ Tokyo PROCESS FOR TREATING MALLED MESOTHELIOMA
EP2767549A1 (en) 2013-02-19 2014-08-20 Adienne S.A. Anti-CD26 antibodies and uses thereof
US11273217B2 (en) 2015-09-11 2022-03-15 Y's Ac Co., Ltd. Cancer treatment composition combining anti-CD26 antibody and other anticancer agent

Also Published As

Publication number Publication date
BR112023022724A2 (pt) 2024-02-20
IL308373A (en) 2024-01-01
EP4337693A1 (en) 2024-03-20
AU2022271679A9 (en) 2023-12-21
AU2022271679A1 (en) 2023-12-07
KR20240007229A (ko) 2024-01-16
CN117580866A (zh) 2024-02-20
CA3218127A1 (en) 2022-11-17
WO2022238978A1 (en) 2022-11-17
JP2024517337A (ja) 2024-04-19

Similar Documents

Publication Publication Date Title
EA202092933A1 (ru) Антитела к entpd2, виды комбинированной терапии и способы применения антител и видов комбинированной терапии
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
EA202192090A1 (ru) Антигенсвязывающие белки против гамма-цепи рецептора il2
MX2021004808A (es) Anticuerpos contra la epcam, anticuerpos activables e inmunoconjugados y usos de estos.
WO2021231237A3 (en) Antibodies for sars-cov-2 and uses thereof
MX2023002106A (es) Anticuerpos fgfr3 y metodos de uso.
ZA202008095B (en) Humanized antibodies against psma
MX2020006171A (es) Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer.
MX2022014995A (es) Metodos de tratamiento de la nefropatia por iga con un anticuerpo de union a april.
CR20210548A (es) Materiales y métodos para modular la inmunidad mediada por células t
MX2021006362A (es) Anticuerpos de dominio simple contra cll-1.
MX2024002238A (es) Anticuerpos anti-ccr8 y uso de los mismos.
MX2021009975A (es) Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer.
MX2022008255A (es) Anticuerpo anti-il-13 para usarse en el tratamiento de esofagitis eosinofilica.
CR20220392A (es) ANTICUERPOS CONTRA LA INTEGRINA avß8 PARA SU USO EN EL TRATAMIENTO DE LA ENFERMEDAD RENAL
CR20230581A (es) Anticuerpos anti-CCR8 y usos de los mismos
MX2022014224A (es) Construcciones de anticuerpos de dominio individual neutralizantes contra sars-cov2.
MX2023001776A (es) Anticuerpos contra ilt2 y uso de los mismos.
MX2022004194A (es) Anticuerpos contra el receptor de virus de la polio (pvr) y usos de los mismos.
MX2021011040A (es) Anticuerpos dirigidos contra c5ar.
MX2023013726A (es) Anticuerpos multiespecificos anti-cea y anti-cd137 y metodos de uso.
MX2023002948A (es) Métodos y composiciones para modular la inmunidad mediada por cadena beta.
MX2023012633A (es) Metodos de tratamiento de la enfermedad de injerto contra hospedero.
MX2022013920A (es) Anticuerpos anti-antigeno asociado con tumor y usos de los mismos.
MX2021008453A (es) Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos.